Survey of European Blood and Marrow Transplant (EBMT) nurses to explore the current topical skin management of chronic cutaneous graft versus host disease in the real-world clinical environment.

Autor: Murray J; Christie NHS Trust Hospital, Manchester, United Kingdom. Electronic address: j.murray10@nhs.net., Liptrott S; Ente Ospedaliero Cantonale, Bellinzona, Switzerland., Canesi M; Fondazione IRCCS San Gerardo dei Tintori Paediatric Dept, University Milano Bicocca, Monza, Italy., Mooyaart J; EBMT Statistical Unit, Leiden, Netherlands., Kisch A; Department of Haematology, Oncology and Radiation Physics, Skane University Hospital, Lund, Sweden and Institute of Health Sciences, Lund University, Sweden., Piepenbroek B; EBMT Leiden Study Unit, Leiden, Netherlands., Stringer J; Christie NHS Trust Hospital, Manchester, United Kingdom; University of Manchester, Manchester, United Kingdom.
Jazyk: angličtina
Zdroj: European journal of oncology nursing : the official journal of European Oncology Nursing Society [Eur J Oncol Nurs] 2024 Apr; Vol. 69, pp. 102547. Date of Electronic Publication: 2024 Mar 05.
DOI: 10.1016/j.ejon.2024.102547
Abstrakt: Purpose: To understand the current practice in relation to the management of topical therapy for cutaneous chronic Graft versus Host Disease (ccGvHD) and access to extracorporeal photopheresis (ECP) within European allogeneic haematopoietic cell transplantation centres by a survey of nurses.
Method: This was a multicentre cross-national study at eligible European Blood and Marrow Transplant centres. Eligibility required more than 30% of treated patients having allogeneic haematopoietic cell transplant. Centres performing only autologous stem cell transplants were excluded from the study.
Results: 12% of respondents were unaware of whether their centre had a policy or not for monitoring chronic cutaneous graft versus host disease. Over half had the affiliation of a dermatologist for referral, but only 19% had access to a specialist nurse. Patient education was routinely provided in most of the centres (86%). Results suggested as the severity of a patient's chronic cutaneous graft versus host disease increased, there was a reduction in the amount of topical emollients and steroids employed. Following topical therapies, systemic treatments, and other modalities such as ECP were employed with less focus directed towards topical care.
Conclusions: Topical treatment is the backbone of any treatment paradigm for chronic cutaneous graft versus host disease, however, there is no universally agreed algorithm. Improved skin care may lead to a reduction in the amount of systemic therapy required, thus increasing patients' quality of life. There is little standardisation in the topical management of chronic cutaneous graft versus host disease, despite skin being the most cited organ affected by chronic graft versus host disease, this should be addressed.
Competing Interests: Declaration of competing interest John Murray reports speaker honorarium from Therakos. The rest of the authors declare no competing interests.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: